Abstract 283P
Background
Worldwide, there are approximately 560 000 new cases diagnosed with head and neck cancer and 300 000 deaths each year. In developing countries including Sub-Saharan Africa, head and neck cancer is rare compared to other cancers. The aims of this study are to estimate the incidence and determine the epidemiological characteristics of head and neck cancer in the population of Niger.
Methods
This is a descriptive retrospective study of head and neck cancer cases, reported to the Niger Cancer Registry in the period 1992-2009. Head and neck cancer includes the following: lip, tongue, mouth (floor, palate and other), salivary glands, tonsils, pharynx (oro-, naso- and hypopharynx), larynx, nose, ear, head and neck not otherwise specified.
Results
In 1992-2009, there were 344 cases diagnosed with head and neck cancer in Niger, which was 4.89% of all cases of cancer reported during this period, with a male-female ratio of 1.49. The incidence rate of head and neck cancer was 2.34 cases per 100 000 persons. Oral cancer was the most common cancer (27.6%), followed by laryngeal and salivary glands cancers (13.1%) and tonsil cancer (10.2%). The mean age at diagnosis of the patients was 42.11±18.24 years. The commonest histological type was squamous cell carcinoma in 27.1% of cases. We registered 11 deaths, with a fatality rate of 3.19%.
Conclusions
Although the incidence rates for head and neck cancers are lower, these cancers include a diverse group of uncommon tumors that frequently are aggressive. Because of the seriousness of cancer in Niger; the health authorities should pay more attention to this pathology through efficient fight strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session